Among other newly approved drugs, Eli Lilly expects that Kisunla, Ebglyss, and Omvoh will be major growth drivers for its portfolio in 2025. In mid-January, Eli Lilly released preliminary revenue ...

EXTON, PA, Jan. 31, 2025 (GLOBE NEWSWIRE) -- The FDA's approval of Eli Lilly’s Omvoh for Crohn’s disease marks a significant milestone as the therapy becomes the second IL-23 inhibitor ...

Eli Lilly and Company (NYSE: LLY) announced results from the VIVID-2 open-label extension study, which showed the majority of patients with moderately to severely active Crohn's disease receiving two ...

Omvoh (mirikizumab-mrkz) has potential interactions with certain vaccines and health conditions. These interactions could cause harmful effects in some people. Omvoh is used in adults to treat ...

Not long after reporting phase 2 data for one of its obesity candidates that appeared to put it on par with Eli Lilly’s Zepbound, Kailera Therapeutics is preparing for an eventual market launch ...

On an investment spree with billions of dollars’ worth of projects ongoing globally, Indianapolis-based Eli Lilly and Company chose Kenosha County for its latest – and one of its largest ...

Eli Lilly and Co.’s approval for Omvoh to treat moderate to severe Crohn’s disease in adults marks the Indianapolis company’s growing presence in the treatment of inflammatory bowel disease.

If Eli Lilly has its way, this may be the future of obesity care. Eli Lilly makes some of the most powerful weight-loss drugs in the world. The company has pivoted dramatically over the past ...

Eli Lilly is experiencing explosive growth thanks to its diabetes and obesity treatments. Beyond weight loss, the company is quietly building a fast-growing oncology business. This is an enormous ...